LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Agency for the Evaluation of Medicinal Products (EMEA), has issued a positive opinion recommending approval of an expanded Marketing Authorization for CUBICIN ® (daptomycin for injection). The CHMP positive opinion, issued by the EMEA on July 19th, recommends expansion of the CUBICIN label to include right-sided infective endocarditis (RIE) due to Staphylococcus aureus (S. aureus) as well as S. aureus bacteremia (SAB) when associated with RIE or with complicated skin and soft-tissue infections (cSSTI). The Marketing Authorization Holder for CUBICIN in Europe is Novartis. CUBICIN was originally approved by the EMEA in January of 2006 for cSSTI caused by Gram-positive bacteria.